Classifications

• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
  • A61K36/18—Magnoliophyta (angiosperms)
  • A61K36/185—Magnoliopsida (dicotyledons)
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K8/00—Cosmetics or similar toiletry preparations
  • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
  • A61K8/19—Cosmetics or similar toiletry preparations characterised by the composition containing inorganic ingredients
  • A61K8/25—Silicon; Compounds thereof
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K8/00—Cosmetics or similar toiletry preparations
  • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
  • A61K8/19—Cosmetics or similar toiletry preparations characterised by the composition containing inorganic ingredients
  • A61K8/27—Zinc; Compounds thereof
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K8/00—Cosmetics or similar toiletry preparations
  • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
  • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
  • A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
  • A61K8/36—Carboxylic acids; Salts or anhydrides thereof
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K8/00—Cosmetics or similar toiletry preparations
  • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
  • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
  • A61K8/49—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds
  • A61K8/4906—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with one nitrogen as the only hetero atom
  • A61K8/4913—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with one nitrogen as the only hetero atom having five membered rings, e.g. pyrrolidone carboxylic acid
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K8/00—Cosmetics or similar toiletry preparations
  • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
  • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
  • A61K8/67—Vitamins
  • A61K8/671—Vitamin A; Derivatives thereof, e.g. ester of vitamin A acid, ester of retinol, retinol, retinal
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K8/00—Cosmetics or similar toiletry preparations
  • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
  • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
  • A61K8/67—Vitamins
  • A61K8/673—Vitamin B group
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K8/00—Cosmetics or similar toiletry preparations
  • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
  • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
  • A61K8/67—Vitamins
  • A61K8/673—Vitamin B group
  • A61K8/675—Vitamin B3 or vitamin B3 active, e.g. nicotinamide, nicotinic acid, nicotinyl aldehyde
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K8/00—Cosmetics or similar toiletry preparations
  • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
  • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
  • A61K8/67—Vitamins
  • A61K8/676—Ascorbic acid, i.e. vitamin C
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K8/00—Cosmetics or similar toiletry preparations
  • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
  • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
  • A61K8/67—Vitamins
  • A61K8/678—Tocopherol, i.e. vitamin E
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K8/00—Cosmetics or similar toiletry preparations
  • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
  • A61K8/72—Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds
  • A61K8/73—Polysaccharides
  • A61K8/732—Starch; Amylose; Amylopectin; Derivatives thereof
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K8/00—Cosmetics or similar toiletry preparations
  • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
  • A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
  • A61K8/97—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
  • A61K8/9783—Angiosperms [Magnoliophyta]
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K8/00—Cosmetics or similar toiletry preparations
  • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
  • A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
  • A61K8/97—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
  • A61K8/9783—Angiosperms [Magnoliophyta]
  • A61K8/9789—Magnoliopsida [dicotyledons]
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
  • A61Q15/00—Anti-perspirants or body deodorants
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
  • A61Q17/00—Barrier preparations; Preparations brought into direct contact with the skin for affording protection against external influences, e.g. sunlight, X-rays or other harmful rays, corrosive materials, bacteria or insect stings
  • A61Q17/04—Topical preparations for affording protection against sunlight or other radiation; Topical sun tanning preparations
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
  • A61Q19/00—Preparations for care of the skin
  • A61Q19/008—Preparations for oily skin
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
  • A61K2800/40—Chemical, physico-chemical or functional or structural properties of particular ingredients
  • A61K2800/59—Mixtures
  • A61K2800/592—Mixtures of compounds complementing their respective functions
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
  • A61K2800/74—Biological properties of particular ingredients
  • A61K2800/78—Enzyme modulators, e.g. Enzyme agonists
  • A61K2800/782—Enzyme inhibitors; Enzyme antagonists

Definitions

• the present invention relates to a new cosmetic composition that can reduce the oiliness and shine of the skin.
• the cosmetic composition comprises at least one sebaceous secretion inhibitor containing Zinc salt compounds, Bixa Orellana seed extract (Urucum), at least one filler and at least one vitamin.
• the present invention is related to the use of said cosmetic composition for the manufacture of a product for reducing the oiliness and shine of the skin.
• the sebum is an oily substance secreted by the sebaceous glands that are found on nearly every surface of the body. Due to its unique composition, the sebum seals the moisture/humidity and prevents skin from becoming over dry. It also has antibacterial properties and antifungal protection making it the body’s first defense against external infection.
• the sebaceous glands are formed by cells of pyknotic nucleus and located in the dermis. Said cells discharge its lipid content in the hair follicles on the skin surface. This content is referred to as “sebum” or tallow, which is therefore a holocrine secretion, comprising 92-100% of lipids (EBLING & ROOK, 1979).
• the sebaceous secretion is composed of several types of fats: triglycerides, free fatty acids, esterified waxes, squalene and cholesterol.
• T-zone which includes the forehead, nose and chin), back, chest, ears, armpits, genitals and scalp.
• Oily skin is shiny, thick, having dilated infundibulum of the pilo-sebaceous follicle (pore), especially in seborrheic regions, and tendency to acne development (CUNLIFFE & COTTERILL, 1975). This clinical aspect is aesthetically unpleasant, and this implies the need to develop specific products for oily skin.
• the sebum production varies from person to person and depends on sex and age. When too much sebum is secreted, an objectionable greasy appearance or shining face are observed. This excess of sebum combined with dead skin cells can also block pores, causing irritation and inflammation of the pores, leading to acne formation in the skin.
• the inventors of the present invention developed a new cosmetic composition that provides not only oiliness and shine control just after the application, but also is capable to control the production of oiliness and shine of the skin with the constant use.
• the cosmetic composition of the present invention surprisingly proven to be effective in two actions: controlling the oiliness and shine, as well as reducing the sebum production of the skin during its use.
• the cosmetic composition according to the present invention showed oiliness and shine control just after application, quick absorption, lasting clean skin sensation until the end of the day (12 hours clean skin sensation), oiliness control through the day, non-oily skin touch, non-oily-texture, clean touch, and dry touch and specially, reduction of sebum production of the skin with the constant use.
• the inventors succeeded to overcome the problems of the state of the art and surprisingly revealed a cosmetic composition having the aforementioned technical advantages.
• the present invention is directed to a cosmetic composition
• a cosmetic composition comprising:
• the present invention is related to the use of said cosmetic composition for the manufacture of a product for reducing the oiliness and shine of the skin.
• Figure 1 Clinical assessment of the oiliness reduction of the cosmetic composition according to Example 1 , indicating a statistically significant improvement of shine/radiance, after 7, 14 and 28 days of product use in comparison to the initial time-point (TO).
• Figure 2 Clinical assessment of the shine reduction of the cosmetic composition according to Example 1 , indicating a statistically significant improvement of oiliness/tactile, after 7, 14 and 28 days of product use in comparison to the initial time-point (TO).
• Figure 3 Shine reduction evaluation of Example 1 of frontal and lateral images of subject’s faces through Visia CR® and image evaluation for skin performed using the image J® software, in which a reduction of shine of the cheek area was observed after 7 and 14 days of product use in comparison to the initial time-point (TO) and a tendency of shine reduction was also observed on the cheek area after 28 days of product use in comparison to the initial time-point (TO).
• TO initial time-point
• Figure 4 Shine reduction evaluation for Example 1 of frontal and lateral images of subject’s faces through Visia CR® and image evaluation for skin performed using the image J® software, in which a reduction of shine of forehead area was observed after 7 and 14 days of product use in comparison to the initial time-point (TO) and a tendency of shine reduction of forehead area was also observed after 28 days of product use in comparison to TO.
• TO initial time-point
• Figure 5 Shine reduction evaluation for Example 1 of frontal and lateral images of subject’s faces through Visia CR® and image evaluation for skin performed using the image J® software, in which a reduction of shine of full-face area was observed after 7, 14 and 28 days of product use in comparison to the initial time-point (TO).
• TO initial time-point
• Figure 6 Oiliness instrumental measurement for Example 1 by Sebumeter® SM 815, in which a reduction of oiliness was observed after 7, 14 and 28 days of product use in comparison to the initial time-point (TO).
• TO initial time-point
• Figure 7 Oiliness instrumental measurement for Example 1 by Sebufix® SF16+ Visioscan® Vc 20plus to analyze the count of oily points, in which a statistically significant higher count of oily spots was observed 7 days of product use in comparison to the initial time-point (TO), and in comparison, to 14 and 28 days of product use.
• TO initial time-point
• Figure 8 Oiliness instrumental measurement for Example 1 by Sebufix® SF16+ Visioscan® Vc 20plus to analyze the percentage of oily area, in which statistically significant lower percentage of oily area after 7,14 and 28 days of product use in comparison to the initial time-point (TO), indicating a reduction in skin oiliness.
• TO initial time-point
• Figure 9 Oiliness instrumental measurement for Example 1 by Sebufix® SF16+ Visioscan® Vc 20plus to analyze the average spot size, in which a lower average spot size was also observed after 7, 14 and 17 days of product use in comparison to the initial time-point (TO), indicating a reduction in the sebum spot size.
• Figure 10 Oiliness instrumental measurement for Example 1 by Sebufix® SF16+ Visioscan® Vc 20plus to analyze the gradient of the percentage of oily area per second, in which a lower value observed after 7, 14 and 28 days of product use in comparison to the initial time-point (TO), indicating a reduction in the sebum production rate.
• TO initial time-point
• FIG 11 Comparative assessment of film form surface parameter (Gc) observed in Example 9 (composition of the present invention) compared to Example 8 (state of the art), indicating that the composition of the present invention presents a statistically significant higher film surface.
• Figure 12 Comparative assessment of contrast gloss parameter (Gc) observed in Example 9 (composition of the present invention) compared to Example 8 (state of the art at time-point THammam, indicating that the composition of the present invention presented lower shine after application.
• the cosmetic composition of the present invention comprises:
• At least one filler selected from silica silylate, silica, perlite and mixtures thereof;
• the amount of the at least one sebaceous secretion inhibitor compound of the present invention is in a range of from about 0.01 % to about 5.0 % by weight, preferably from about 0.05 % to about 3.0 % by weight, more preferably from about 0.1 % to about 2.0 % by weight, based on the total weight of the composition.
• the at least one sebaceous secretion inhibitor containing Zinc salt compound is selected from zinc salt of L-pyrrolidone carboxylic acid (zinc PCA), zinc sulfate, zinc acetate, zinc octate, zinc oxide, and mixtures thereof.
• the at least one sebaceous secretion inhibitor is zinc salt of L-pyrrolidone carboxylic acid (zinc PCA).
• the amount of Bixa Orellana seed extract (Urucum) of the present invention ranges from about 0.01 % to about 5.0 % by weight, more preferably from about 0.1 % to about 3.0 % by weight, more preferably from about 0.2 % to about 2.0 % by weight, based on the total weight of the composition.
• the Bixa Orellana seed extract (Urucum) may be in a liquid, solid, emulsion, gel, or powder form. Also, the Bixa Orellana seed extract (Urucum) may be encapsulated or non-encapsulated.
• the Bixa Orellana seed extract refers to said extract in its pure form, or in a blend with polysaccharides, for example, but not limited to, maltodextrin or Arabic gum.
• the Bixa Orellana seed extract (Urucum) of the present invention is a blend of Bixa Orellana seed extract (Urucum) and maltodextrin.
• the amount of Bixa Orellana seed extract (Urucum) in the blend ranges from about 30 % to about 50%, and the amount of maltodextrin in the blend ranges from about 50 % to about 70 %, based on the total weight of the extract.
• the amount of at least one filler of the present invention ranges from about 0.01 % to about 20 % by weight, more preferably from about 0.1 % to about 10 % by weight, more preferably from about 0.2 % to about 7 %, based on the total weight of the composition.
• the at least one filler of the present invention is silica silylate.
• the amount of at least one vitamin of the present invention ranges from about 0.01 % to about 10.0 % by weight, more preferably from about 0.1 % to about 5.0 % by weight, based on the total weight of the composition.
• the at least one vitamin of the present invention is a vitamin of complex B, more specifically, vitamin B3 (niacinamide).
• the cosmetic composition of the present invention may further comprise at least one UV filter, selected from the group of inorganic UV filters, organic UV filters, and mixtures thereof.
• the UV filters of the present invention are organic UV filters selected from group of butyl methoxydibenzoylmethane, ethylhexyl salicylate, ethylhexyl triazone, terephthalylidene dicamphor sulfonic acid, drometrizole trisiloxane, bis-ethylhexyloxyphenol methoxyphenyl triazine and mixtures thereof.
• the amount of the UV filter ranges from about 0.1 % to about 40.0 % by weight, preferably from about 1 .0 % to about 30.0 % by weight, based on the total weight of the composition.
• composition of the present invention may be a sunscreen product, presenting a SPF of 30, 50, 60, 70, 90 or 100.
• the cosmetic composition of the present invention may be tinted or non-tinted.
• the cosmetic composition of the present invention is in the form of dry fluid, oil-in-water emulsion or water-in-oil emulsion and can be used as a daily product for skincare or sunscreen (suncare) products.
• the cosmetic composition according to the present invention reduces the oiliness and shine of the skin, due to a composition comprising at least one sebaceous secretion inhibitor containing Zinc salt compounds, Bixa Orellana seed extract (Urucum), at least one filler and at least one vitamin.
• the cosmetic composition according to the present invention showed oiliness and shine control of the skin just after application, quick absorption, clean skin sensation until the end of the day (12 hours clean skin sensation), oiliness control through the day, non-oily touch of the skin, non-oily-texture, clean touch, and dry touch. Also, the composition of the present invention was able to reduce the oiliness and sebum production of the skin in seven days of use.
• the present invention is related to the use of the cosmetic composition for manufacturing a product (skin care or suncare products) for reducing the oiliness and shine of the skin.
• the cosmetic composition of the present invention comprises: a) from about 0.01 % to about 5.0 % by weight, of at least one sebaceous secretion inhibitor containing Zinc salt compounds, selected from zinc salt of L-pyrrolidone carboxylic acid (zinc PCA), zinc sulfate, zinc acetate, zinc octate, zinc oxide, and mixtures thereof;
• the cosmetic composition of the present invention comprises: a) from about 0.05 % to about 3.0 % by weight, of at least one sebaceous secretion inhibitor containing zinc salt compounds selected from zinc salt of L-pyrrolidone carboxylic acid (zinc PCA), zinc sulfate, zinc acetate, zinc octate, zinc oxide, and mixtures thereof;
• at least one sebaceous secretion inhibitor containing zinc salt compounds selected from zinc salt of L-pyrrolidone carboxylic acid (zinc PCA), zinc sulfate, zinc acetate, zinc octate, zinc oxide, and mixtures thereof;
• the cosmetic composition of the present invention may comprise UV filters and may be tinted or non-tinted.
• the process of manufacturing the cosmetic composition of the present invention comprises the following steps. Particularly, four phases were prepared:
• Phase A Water phase comprising a mixture of the hydrophilic actives chosen from the at least one sebaceous secretion inhibitor, Bixa Orellana seed extract and vitamin;
• Phase B Oily phase comprising a mixture of the lipophilic actives chosen from the at least one sebaceous secretion inhibitor, Bixa Orellana seed extract and vitamin; • Phase C: Emulsion phase comprising Phase A and Phase B; and
• phase A is prepared by mixing the hydrophilic actives under agitation ranging from about 200 rpm to 600 rpm and within a temperature ranging from about 25 o C to about 70 °C.
• phase B is prepared by mixing the lipophilic actives and then heating until the total fusion of the ingredients.
• an emulsion step is prepared by adding phase A into phase B, under a temperature of at least 65 o C with high shear, and after phases A and B are combined, they form phase C.
• phase D After the emulsion is formed, all powders and fillers are added into the emulsion as a final step (phase D).
• the composition is finalized when the temperature achieves 30°C or less.
• the expression “at least” means one or more and thus includes individual components as well as mixtures/combinations.
• ranges provided are meant to include every specific range within, and combination of sub ranges between, the given ranges.
• a range from 1 -5 includes specifically 1 , 2, 3, 4 and 5, as well as sub ranges such as 2-5, 3-5, 2-3, 2-4, 1 -4, etc.
• All ranges and values disclosed herein are inclusive and combinable. For examples, any value or point described herein that falls within a range described herein can serve as a minimum or maximum value to derive a sub-range, etc.
• a mixture thereof does not require that the mixture include all of A, B, C, D, E, and F (although all of A, B, C, D, E, and F may be included). Rather, it indicates that a mixture of any two or more of A, B, C, D, E, and F can be included. In other words, it is equivalent to the phrase “one or more elements selected from the group consisting of A, B, C, D, E, F, and a mixture of any two or more of A, B, C, D, E, and F”.
• the sebaceous secretion inhibitor used in the present invention comprises zinc salt compounds, which can be salts or complex of zinc used in skin products, selected from: zinc salt of L-pyrrolidone carboxylic acid (Zinc-PCA), zinc sulfate, zinc acetate, zinc octate, zinc oxide and mixtures thereof.
• Zinc-PCA zinc salt of L-pyrrolidone carboxylic acid
• Zinc-PCA zinc sulfate
• zinc acetate zinc octate
• zinc oxide zinc oxide
• Zinc is used in cosmetic field to form nonvolatile salts with fatty acids and other substances and exert antibacterial activity.
• the dihydrotestosterone (DHT) a metabolic product of testosterone, produced by the action of the enzyme 5-alpha- reductase, stimulates sebaceous glands to produce and secrete sebum.
• the Zinc compounds inhibits such 5-reductase activity.
• the zinc- containing compound is Zinc PCA (INCI name), which is the zinc salt of pyrrolidone carboxylic acid and acts as an active ingredient to control the oiliness in the present cosmetic composition (sebum inhibitors).
• the sebaceous secretion inhibitor compounds range from about 0.01 % to about 5.0 % by weight, based on the total weight of the composition.
• the extract used in the present invention is Bixa Orellana Seed Extract (INCI Name), which is from Bixaceae family.
• the Bixa Orellana seeds extract is also known as Urucum, Roucou, Red lips tree, Achiote, annatto, or kusuwe.
• the Bixa Orellana seeds extract of the present invention promotes the decreasing the hyper keratinization and inhibits the virulence of P.acnes, sebaceous gland activity, pore size, and skin imperfections, while maintaining the hydration and matte skin sensation.
• the Bixa Orellana seed extract can be used in the present invention in a liquid, solid, emulsion, gel, or powder form, and can be encapsulated or nonencapsulated.
• the Bixa Orellana seed extract refers to said extract in its pure form, or in a blend with polysaccharides, for example, but not limited to, maltodextrin or Arabic gum.
• the Bixa Orellana seed extract (Urucum) of the present invention is a blend of Bixa Orellana seed extract (Urucum) and maltodextrin.
• the amount of Bixa Orellana seed extract (Urucum) in the blend ranges from about 30.0 % to about 50.0 %, and the amount of maltodextrin in the blend ranges from about 50.0 % to about 70.0 %, based on the total weight of the extract.
• the amount of the Bixa Orellana seeds extract (Urucum) in the composition of the present invention ranges from about 0.01 % to about 5.0 % by weight, more preferably from about 0.1 % to about 3.0 % by weight, more preferably from about 0.2 % to about 2.0 % by weight, based on the total weight of the composition.
• the cosmetic composition according to the present invention comprises at least one filler selected from the group of: silica silylate, silica, perlite and mixtures thereof.
• the filler used in the cosmetic composition of the present invention is silica silylate.
• the “silica silylate” according to the present invention is a porous material obtained by replacing (by drying) the liquid component of a silica gel with air.
• Silica aerogels are generally synthesized via a sol-gel process in a liquid medium and then dried, usually by extraction with a supercritical fluid, such as, but not limited to, supercritical carbon dioxide (CO2). This type of drying makes it possible to avoid shrinkage of the pores and of the material.
• a supercritical fluid such as, but not limited to, supercritical carbon dioxide (CO2).
• the silica silylate particles used in the present invention have a specific surface area per unit of mass (SM) ranging from about 500 to about 1500 m 2 /g, or alternatively from about 600 to about 1200 m 2 /g, or alternatively from about 600 to about 800 m 2 /g, and a size expressed as the mean volume diameter (D[0.5]), ranging from about 1 to about 30 pm, or alternatively from about 5 to about 25 pm, or alternatively from about 5 to about 20 pm, or alternatively from about 5 to about 15 pm.
• the specific surface area per unit of mass may be determined via the BET (Brunauer- Emmett-Teller) nitrogen absorption method described in the Journal of the American Chemical Society, vol. 60, page 309, February 1938, corresponding to the international standard ISO 5794/1 .
• the BET specific surface area corresponds to the total specific surface area of the particles under consideration.
• the size of the silica silylate particles may be measured by static light scattering using a commercial granulometer such as the MasterSizer 2000 machine from Malvern.
• the data are processed on the basis of the Mie scattering theory.
• This theory which is exact for isotropic particles, makes it possible to determine, in the case of non-spherical particles, an “effective” particle diameter. This theory is especially described in the publication by Van de Hulst, H.C., “Light Scattering by Small Particles,” Chapters 9 and 10, Wiley, New York, 1957.
• the silica silylate particles used in the present invention may advantageously have a tamped (or tapped) density ranging from about 0.04 g/cm 3 to about 0.10 g/cm 3 ’ or alternatively from about 0.05 g/cm 3 to about 0.08 g/cm 3 .
• this density may be assessed according to the following protocol: 40 g of powder are poured into a measuring cylinder; the measuring cylinder is then placed on a Stav 2003 machine from Stampf Volumeter; the measuring cylinder is then subjected to a series of 2500 packing motions (this operation is repeated until the difference in volume between two consecutive tests is less than 2%); the final volume Vf of packed powder is then measured directly on the measuring cylinder.
• the tamped density is determined by the ratio m/Vf, in this instance 40/Vf (Vf being expressed in cm 3 and m in g).
• the silica silylate particles used in the present invention have a specific surface area per unit of volume Sv ranging from about 5 to about 60 m 2 /cm 3 , or alternatively from about 10 to about 50 m 2 /cm 3 , or alternatively from about 15 to about 40 m 2 /cm 3 .
• the silica silylate particles have an oil-absorbing capacity, measured at the wet point, ranging from about 5 to about 18 ml/g, or alternatively from about 6 to about 15 ml/g, or alternatively from about 8 to about 12 ml/g.
• the oil-absorbing capacity measured at the wet point corresponds to the amount of water that needs to be added to 100 g of particle in order to obtain a homogeneous paste. Wp is measured according to the wet point method or the method for determining the oil uptake of a powder described in standard NF T 30-022.
• Wp corresponds to the amount of oil adsorbed onto the available surface of the powder and/or absorbed by the powder by measuring the wet point, described below:
• An amount 2 g of powder is placed on a glass plate, and the oil (isononyl isononanoate) is then added dropwise.
• mixing is performed using a spatula, and addition of oil is continued until a conglomerate of oil and powder has formed.
• the oil is added one drop at a time and the mixture is then triturated with the spatula.
• the addition of oil is stopped when a firm, smooth paste is obtained. This paste must be able to be spread on the glass plate without cracking or forming lumps.
• the volume Vs (expressed in ml) of oil used is then noted.
• the oil uptake corresponds to the ratio Vs/m.
• the silica silylate according to the present invention is a hydrophobic silica aerogel.
• hydrophobic silica means any silica whose surface is treated with silylating agents, for example, halogenated silanes, such as alkylchlorosilanes, siloxanes, in particular dimethylsiloxanes, such as hexamethyldisiloxane, or silazanes, so as to functionalize the OH groups with silyl groups Si-Rn, for example, trimethylsilyl groups.
• silylating agents for example, halogenated silanes, such as alkylchlorosilanes, siloxanes, in particular dimethylsiloxanes, such as hexamethyldisiloxane, or silazanes, so as to functionalize the OH groups with silyl groups Si-Rn, for example, trimethylsilyl groups.
• silica silylate particles surface-modified with trimethylsilyl groups are desirable
• silica silylate may include, but are not limited to, the aerogels sold under the tradenames of VM-2260 (INCI name: Silica silylate) and VM-2270 (INCI name: Silica silylate), both available from Dow Corning Corporation (Midland, Michigan).
• the particles of VM-2260 have a mean size of about 1000 microns and a specific surface area per unit of mass ranging from 600 to 800 m 2 /g.
• the particles of VM-2270 have a mean size ranging from 5 to 15 microns and a specific surface area per unit of mass ranging from 600 to 800 m 2 /g.
• hydrophobic silica aerogel may include, but is not limited to, the aerogels commercially available from Cabot Corporation (Billerica, Massachusetts) under the tradename of Aerogel TLD 201 , Aerogel OGD 201 and Aerogel TLD 203, Enova Aerogel MT 1 100 and Enova Aerogel MT 1200.
• the amount of at least one filler ranges from about 0.01% to about 20 % by weight, more preferably from about 0.1 % to about 10% by weight, more preferably from about 0.2 % to about 7 %, based on the total weight of the composition.
• the cosmetic composition of the present invention also comprises at least one vitamin, selected from: vitamin A, complex B, vitamin C, vitamin E and mixtures thereof.
• the vitamin is a complex B vitamin, selected from vitamin B3 (niacinamide), B5 (panthenol), B6 (Pyridoxine Hydrochloride), B7 (Biotin) and B9 (Folic Acid). More preferably, the at least one vitamin of the present invention is vitamin B3 (niacinamide).
• the vitamin is a mixture of vitamin E and complex B, preferably tocopherol and niacinamide, respectively.
• the amount of at least one vitamin ranges from about 0.01 % to about 10.0 % by weight, more preferably from about 0.1 % to about 5.0 % by weight, based on the total weight of the composition.
• composition according to the present invention further comprises at least one UV filter, selected from inorganic, organic UV filters and mixtures thereof.
• the UV filter can comprise least one inorganic UV filter. If two or more inorganic UV filters are used, they may be the same or different.
• the inorganic UV filter used for the present invention may be active in the UV-A and/or UV-B region.
• the inorganic UV filter may be hydrophilic and/or lipophilic.
• the inorganic UV filter is in some embodiments insoluble in solvents, such as water, and ethanol commonly used in cosmetics.
• the inorganic UV filter be in the form of a fine particle such that the mean (primary) particle diameter thereof ranges from about 1 nm to about 50 nm, and in some embodiments from about 5 nm to about 40 nm, and in some embodiments from about 10 nm to about 30 nm.
• the mean (primary) particle size or mean (primary) particle diameter here is an arithmetic mean diameter.
• the inorganic UV filter can be selected from the group consisting of silicon carbide, metal oxides which may or may not be coated, and mixtures thereof. And in some embodiments, the inorganic UV filters are selected from pigments (mean size of the primary particles: generally from about 5 nm to about 50 nm, and in some embodiments from about 10 nm to about 50 nm) formed of metal oxides, such as, for example, pigments formed of titanium oxide (amorphous or crystalline in the rutile and/or anatase form), iron oxide, zinc oxide, zirconium oxide, or cerium oxide, which are all UV photoprotective agents that are well known per se.
• pigments mean size of the primary particles: generally from about 5 nm to about 50 nm, and in some embodiments from about 10 nm to about 50 nm
• metal oxides such as, for example, pigments formed of titanium oxide (amorphous or crystalline in the rutile and/or anatase form), iron oxide, zinc oxide, zir
• the inorganic UV filters are selected from titanium oxide, zinc oxide, and, in some embodiments, titanium oxide.
• the inorganic UV filter may or may not be coated.
• the inorganic UV filter may have at least one coating.
• the coating may comprise at least one compound selected from the group consisting of alumina, silica, aluminum hydroxide, silicones, silanes, fatty acids or salts thereof (such as sodium, potassium, zinc, iron, or aluminum salts), fatty alcohols, lecithin, amino acids, polysaccharides, proteins, alkanolamines, waxes, such as beeswax, (meth)acrylic polymers, organic UV filters, and (per)fluoro compounds.
• the coating may include at least one organic UV filter.
• a dibenzoylmethane derivative such as butyl methoxydibenzoylmethane (Avobenzone) and 2,2'-Methylenebis[6-(2H- Benzotriazol-2-yl)-4-(l,l,3,3-Tetramethyl-Butyl) Phenol] (Methylene Bis-Benzotriazolyl Tetramethylbutylphenol), such as marketed as “TINOSORB M” by BASF, may be desirable.
• the silicones in the coating(s) may be organosilicon polymers or oligomers comprising a linear or cyclic and branched or cross-linked structure, of variable molecular weight, obtained by polymerization and/or polycondensation of suitable functional silanes and essentially composed of repeated main units in which the silicon atoms are connected to one another via oxygen atoms (siloxane bond), optionally substituted hydrocarbon radicals being connected directly to said silicon atoms via a carbon atom.
• silanes also encompasses silanes necessary for their preparation, in particular alkylsilanes.
• the silicones used for the coating(s) can be and in some embodiments are selected from the group consisting of alkylsilanes, polydialkylsiloxanes, and polyalkylhydrosiloxanes. And in some embodiments still, the silicones are selected from the group consisting of octyltrimethylsilane, polydimethylsiloxanes, and polymethylhydrosiloxanes.
• the inorganic UV filters made of metal oxides may, before their treatment with silicones, have been treated with other surfacing agents, in particular with cerium oxide, alumina, silica, aluminum compounds, silicon compounds, or their mixtures.
• the coated inorganic UV filter may have been prepared by subjecting the inorganic UV filter to one or more surface treatments of a chemical, electronic, mechano-chemical, and/or mechanical nature with any of the compounds as described above, as well as polyethylene waxes, metal alkoxides (titanium or aluminum alkoxides), metal oxides, sodium hexametaphosphate, and those shown, for example, in Cosmetics & Toiletries, February 1990, Vol. 105, pp. 53-64.
• the coated inorganic UV filters may be titanium oxides coated: with silica, such as the product “Sun veil” from Ikeda, and “Sunsil TIN 50” from Sunjin Chemical; with silica and with iron oxide, such as the product “Sunveil F” from Ikeda; with silica and with alumina, such as the products “Microtitanium Dioxide MT 500 SA” from Tayca, “Tioveil” from Tioxide, and “Mirasun TiW 60” from Rhodia; with alumina, such as the products “Tipaque TTO-55 (B)” and “Tipaque TTO-55 (A)” from Ishihara, and “UVT 14/4” from Kemira; with alumina and with aluminum stearate, such as the product “Microtitanium Dioxide MT 100 T, MT 100 TX, MT 100 Z or MT-01” from Tayca, the products “Solaveil CT-10 W”
• titanium oxide pigments treated with a silicone are, and in some embodiments TiO2 treated with octyltrimethylsilane and for which the mean size of the individual particles is from 25 and 40 nm, such as that marketed under the trademark “T 805” by Degussa Silices, TiO2 treated with a polydimethylsiloxane and for which the mean size of the individual particles is 21 nm, such as that marketed under the trademark “70250 Cardre UF TiO2Si3” by Cardre, and anatase/rutile TiO2 treated with a polydimethylhydrosiloxane and for which the mean size of the individual particles is 25 nm, such as that marketed under the trademark “Microtitanium Dioxide USP Grade Hydrophobic” by Color Techniques.
• the following coated TiO 2 can be used as the coated inorganic UV filter: Stearic acid (and) Aluminum Hydroxide (and) TiO2, such as the product “MT-100 TV” from Tayca, with a mean primary particle diameter of 15 nm; Dimethicone (and) Stearic Acid (and) Aluminum Hydroxide (and) TiO 2 , such as the product “S A-TTO-S4” from Miyoshi Kasei, with a mean primary particle diameter of 15 nm; Silica (and) TiO 2 , such as the product “MT-100 WP” from Tayca, with a mean primary particle diameter of 15 nm; Dimethicone (and) Silica (and) Aluminum Hydroxide (and) TiO 2 , such as the product “MT-Y02” and “MT-Y-110 M3S” from Tayca, with a mean primary particle diameter of 10 nm; Dimethicone (and) Aluminum Hydroxide (and) TiO 2 ,
• TiO 2 coated with at least one organic UV filter is more desirable.
• Avobenzone (and) Stearic Acid (and) Aluminum Hydroxide (and) TiO 2 such as the product “HXMT-100ZA” from Tayca, with a mean primary particle diameter of 15 nm, can be used.
• the uncoated titanium oxide pigments are, for example, marketed by Tayca under the trademarks “Microtitanium Dioxide MT500B” or “Microtitanium Dioxide MT600B”, by Degussa under the trademark “P 25”, by Wacker under the trademark “Oxyde de titane transparent PW’, by Miyoshi Kasei under the trademark “UFTR”, by Tomen under the trademark “ITS” and by Tioxide under the trademark “Tioveil AQ”.
• the uncoated zinc oxide pigments are, for example, those marketed under the trademark “Z-cote” by Sunsmart; those marketed under the trademark “Nanox” by Elementis; and those marketed under the trademark “Nanogard WCD 2025” by Nanophase Technologies.
• coated zinc oxide pigments are, for example, those marketed under the trademark “Oxide Zinc CS-5” by Toshiba (ZnO coated with polymethylhydrosiloxane); those marketed under the trademark “Nanogard Zinc Oxide FN” by Nanophase Technologies (as a 40% dispersion in Finsolv TN, C12-C15 alkyl benzoate); those marketed under the trademark “Daitopersion Zn-30” and “Daitopersion Zn-50” by Daito (dispersions in oxyethylenated polydimethylsiloxane/cyclopolymethylsiloxane comprising 30% or 50% of zinc nanooxides coated with silica and polymethylhydrosiloxane); those marketed under the trademark “NFD Ultrafine ZnO” by Daikin (ZnO coated with phosphate of perfluoroalkyl and a copolymer based on perfluoroalkylethyl as a dispersion in cyclopenta
• the uncoated iron oxide pigments are, for example, marketed by Arnaud under the trademarks “Nanogard WCD 2002 (FE 45B)”, “Nanogard Iron FE 45 BL AQ”, “Nanogard FE 45R AQ”, and “Nanogard WCD 2006 (FE 45R)”, or by Mitsubishi under the trademark “TY-220”.
• the coated iron oxide pigments are, for example, marketed by Arnaud under the trademarks “Nanogard WCD 2008 (FE 45B FN)”, “Nanogard WCD 2009 (FE 45B 556)”, “Nanogard FE 45 BL 345”, and “Nanogard FE 45 BL”, or by BASF under the trademark “Oxyde de fer transparent”.
• titanium dioxide and of cerium dioxide including a mixture of equal weights of titanium dioxide coated with silica and of cerium dioxide coated with silica, such as marketed by Ikeda under the trademark “Sunveil A”, and also a mixture of titanium dioxide and of zinc dioxide coated with alumina, with silica and with silicone, such as the product “M 261” marketed by Kemira, or coated with alumina, with silica
• Coated inorganic UV filters are desirable, because the UV filtering effects of the inorganic UV filters can be enhanced.
• the coating(s) may help uniformly or homogeneously disperse the UV filters in the composition, according to the present invention.
• composition according to the present invention, further comprises
• the UV filter can comprise at least one organic UV filter. If two or more organic UV filters are used, they may be the same or different.
• the organic UV filter used for the present invention may be active in the UV- A and/or UV-B region.
• the organic UV filter may be hydrophilic and/or lipophilic.
• the organic UV filter may be solid or liquid.
• solid and liquid mean solid and liquid, respectively, at 25°C under 1 atm.
• the organic UV filter can be selected from the group consisting of anthranilic compounds; dibenzoylmethane compounds; cinnamic compounds; salicylic compounds; camphor compounds; benzophenone compounds; (3, [3-diphenylacrylate compounds; triazine compounds; benzotriazole compounds; benzalmalonate compounds; benzimidazole compounds; imidazoline compounds; bis-benzoazolyl compounds; p-aminobenzoic acid (PABA) compounds; methylenebis(hydroxyphenylbenzotriazole) compounds; benzoxazole compounds; screening polymers and screening silicones; dimers derived from a-alkylstyrene; 4,4- diarylbutadienes compounds; guaiazulene and derivatives thereof; rutin and derivatives thereof; flavonoids; bioflavonoids; oryzanol and derivatives thereof; quinic acid and derivatives thereof; phenols; retinol; cysteine; aromatic amino acids; peptid
• Anthranilic compounds menthyl anthranilates, such as marketed under the trademark “Neo Heliopan MA” by Haarmann and Reimer.
• the dibenzoylmethane compounds Butyl methoxydibenzoylmethane, such as marketed in particular under the trademark “Parsol 1789” by Hoffmann-La Roche; and isopropyl dibenzoylmethane.
• Cinnamic compounds Ethylhexyl methoxycinnamate, such as marketed in particular under the trademark “Parsol MCX” by Hoffmann-La Roche; isopropyl methoxycinnamate; isopropoxy methoxycinnamate; isoamyl methoxycinnamate, such as marketed under the trademark “Neo Heliopan E 1000” by Haarmann and Reimer; cinoxate (2- ethoxyethyl-4-methoxy cinnamate); DEA methoxycinnamate; diisopropyl methylcinnamate; and glyceryl ethylhexanoate dimethoxycinnamate.
• Salicylic compounds Homosalate (homomentyl salicylate), such as marketed under the trademark “Eusolex HMS” by Rona/EM Industries; ethylhexyl salicylate, such as marketed under the trademark “Neo Heliopan OS” by Haarmann and Reimer; glycol salicylate; butyloctyl salicylate; phenyl salicylate; dipropyleneglycol salicylate, such as marketed under the trademark “Dipsal” by Scher; and TEA salicylate, such as marketed under the trademark “Neo Heliopan TS” by Haarmann and Reimer.
• Homosalate homomentyl salicylate
• ethylhexyl salicylate such as marketed under the trademark “Neo Heliopan OS” by Haarmann and Reimer
• glycol salicylate butyloctyl salicylate
• phenyl salicylate dipropyleneglycol salicylate
• TEA salicylate
• Camphor compounds in particular, benzylidenecamphor derivatives: 3-benzylidene camphor, such as manufactured under the trademark “Mexoryl SD” by Chimex; 4- methylbenzylidene camphor, such as marketed under the trademark “Eusolex 6300” by Merck; benzylidene camphor sulfonic acid, such as manufactured under the trademark “Mexoryl SL” by Chimex; camphor benzalkonium methosulfate, such as manufactured under the trademark “Mexoryl SO” by Chimex; terephthalylidene dicamphor sulfonic acid, such as manufactured under the trademark “Mexoryl SX” by Chimex; and polyacrylamidomethyl benzylidene camphor, such as manufactured under the trademark “Mexoryl SW’ by Chimex.
• 3-benzylidene camphor such as manufactured under the trademark “Mexoryl SD” by Chimex
• 4- methylbenzylidene camphor such as
• Benzophenone compounds Benzophenone-1 (2,4-dihydroxybenzophenone), such as marketed under the trademark “llvinul 400” by BASF; benzophenone-2 (Tetrahydroxybenzophenone), such as marketed under the trademark “llvinul D50” by BASF; Benzophenone-3 (2- hydroxy-4-methoxybenzophenone) or oxybenzone, such as marketed under the trademark “llvinul M40” by BASF; benzophenone-4 (hydroxymethoxy benzophonene sulfonic acid), such as marketed under the trademark “llvinul MS40” by BASF; benzophenone-5 (Sodium hydroxymethoxy benzophenone Sulfonate); benzophenone-6 (dihydroxy dimethoxy benzophenone); such as marketed under the trademark “Helisorb 11” by Norquay; benzophenone-8, such as marketed under the trademark “Spectra-Sorb UV-24” by American Cyanamid; benzophenone-9 (Dis
• Triazine compounds Diethylhexyl butamido triazone, such as marketed under the trademark “Uvasorb HEB” by Sigma 3V; 2,4,6-tris(dineopentyl 4'-aminobenzalmalonate)-s-triazine, bisethylhexyloxyphenol methoxyphenyl triazine, such as marketed under the trademark «TINOSORB S >> by CIBA GEIGY, and ethylhexyl triazone, such as marketed under the trademark «UVTNUL T150 >> by BASF.
• Benzotriazole compounds in particular, phenylbenzotriazole derivatives: 2-(2H-benzotriazole-2-yl)-6-dodecyl-4-methylpheno, branched and linear; and those described in USP 5240975.
• Benzalmalonate compounds Dineopentyl 4'-methoxybenzalmalonate, and polyorganosiloxane comprising benzalmalonate functional groups, such as polysilicone-15, such as marketed under the trademark “Parsol SLX” by Hoffmann-LaRoche.
• Benzimidazole compounds in particular, phenylbenzimidazole derivatives: Phenylbenzimidazole sulfonic acid, such as marketed in particular under the trademark “Eusolex 232” by Merck, and disodium phenyl dibenzimidazole tetrasulfonate, such as marketed under the trademark “Neo Heliopan AP” by Haarmann and Reimer.
• Imidazoline compounds Ethylhexyl dimethoxybenzylidene dioxoimidazoline propionate.
• Bis-benzoazolyl compounds The derivatives as described in EP-669,323 and U.S. Pat. No. 2,463,264.
• Para-aminobenzoic acid compounds PABA (p-aminobenzoic acid), ethyl PABA, Ethyl di hydroxypropyl PABA, pentyl dimethyl PABA, ethylhexyl dimethyl PABA, such as marketed in particular under the trademark “Escalol 507” by ISP, glyceryl PABA, and PEG-25 PABA, such as marketed under the trademark “Uvinul P25” by BASF.
• PABA p-aminobenzoic acid
• ethyl PABA Ethyl di hydroxypropyl PABA
• pentyl dimethyl PABA ethylhexyl dimethyl PABA
• PEG-25 PABA such as marketed under the trademark “Uvinul P25” by BASF.
• Methylene bis-(hydroxyphenylbenzotriazol) compounds such as 2,2'- methylenebis[6-(2H-benzotriazol-2-yl)-4-methyl-phenol], such as marketed in the solid form under the trademark “Mixxim BB/200” by Fairmount Chemical, 2,2'- methylenebis[6-(2H-benzotriazol-2-yl)-4-(l,l,3,3-tetramethylbutyl)phenol], such as marketed in the micronized form in aqueous dispersion under the trademark “Tinosorb M” by BASF, or under the trademark “Mixxim BB/100” by Fairmount Chemical, and the derivatives as described in U.S. Pat. Nos.
• Drometrizole trisiloxane such as marketed under the trademark “Silatrizole” by Rhodia Chimie or- “Mexoryl XL” by L’Oreal.
• Benzoxazole compounds 2,4-bis[5-l(dimethylpropyl)benzoxazol-2-yl-(4- phenyl)imino]- 6-(2-ethylhexyl)imino-l,3,5-triazine, such as marketed under the trademark of Uvasorb K2A by Sigma 3V.
• the organic UV filter(s) be selected from the group consisting of: butyl methoxydibenzoylmethane, ethylhexyl methoxycinnamate, homosalate, ethylhexyl salicylate, octocrylene, phenylbenzimidazole sulfonic acid, benzophenone-3, benzophenone-4, benzophenone-5, n-hexyl 2-(4-diethylamino-2-hydroxybenzoyl)benzoate, l,r-(l,4- piperazinediyl)bis[l-[2-[4-(diethylamino)-2-hydroxybenzoyl]phenyl]-methanone 4- methylbenzylidene camphor, terephthalylidene dicamphor sulfonic acid, disodium phenyl dibenzimidazole tetrasulfonate, ethyl
• the amount of the UV filters ranges from about 0.1 % to about 40.0 % by weight, preferably from about 1 .0 % by weight to about 30.0 % by weight, based on the total weight of the composition.
• composition of the invention may further comprise any usual cosmetically acceptable ingredient, which may be chosen especially from such as coated pigments, perfume/f rag rance, preserving agents, solvents, actives, fatty/oil compounds, metal oxides, vitamins, fillers, silicones, polymers, and mixtures thereof.
• the additional ingredients may represent from about 0.5 % to about 98.0 % by weight, based on the total weight of the composition of the invention.
• the cosmetic composition according to Example 1 was tested to assess the oiliness and shine reduction of the skin, immediately after the product application, and after 7, 14 and 28 days under normal use conditions.
• the test was conducted with 20 female subjects from 18 to 50 years old, and the amount of the product applied was enough for the complete coverage of each half-face (315mg). After 10-15 minutes of the products application (time needed for products to dry), the measures were performed.
• the subjects were conducted to a Hot Room (Hammam) with temperature and a relative humidity of 37 °C ⁇ 1 S C and 60% ⁇ 5 RH in which they remained for 2 hours.
• the subjects waited for 20 minutes in acclimatization of 21 °C ⁇ 1 °C and 50% ⁇ 5 RH, in order to prevent the analysis from being biased by the sweat. After this period (THammam), new measures were performed.
• the subjects also applied the product daily, 2 times a day and the subjects received the product for use for 28 ⁇ 2 days.
• a shine analysis of the skin was conducted with 20 female subjects from 18 to 50 years old. The amount of the product applied was enough for the complete coverage of each half-face (315mg). After 10-15 minutes of the products application (time needed for products to dry), the measures were performed.
• Example 1 The test was conducted with 20 female subjects from 18 to 50 years old, and the amount of the product applied was enough for complete coverage of each halfface (315mg). After 10-15 minutes of the products application (time needed for products to dry), the measures were performed. The oiliness of the composition of Example 1 was also evaluated and measured by Instrumental measurement Sebumeter® SM 815. The mean result is shown in Figure 6.
• the cosmetic composition according to Example 1 was tested to assess the oiliness of the skin, immediately after the product application, and after 7, 14 and 28 days under normal use conditions.
• the test was conducted with 20 female subjects from 18 to 50 years old, and the amount of the product applied was enough for the complete coverage of each half-face (315mg). After 10-15 minutes of the products application (time needed for products to dry), the measures were performed.
• Example 1 The oiliness of the skin regarding the composition of Example 1 was evaluated and measured by Instrumental measurement Sebufix® SF16+ Visioscan® Vc 20plus.
• a comparative analysis was performed to verify the shine and oiliness reduction of two sunscreens products, undergoing variation of temperature and humidity through analysis of images obtained with the devices VISIA® CR and LightCam®.
• the comparative analysis was performed in female subjects, aged between 18 and 50 years old, who feel bothered/discomfortable due to the skin condition.
• the products were applied in the face, two times a day. A total of 49 subjects was evaluated.
• the subjects were conducted to a Hot Room (Hammam) with temperature and a relative humidity of 37°C ⁇ 1 S C and 60% ⁇ 5 RH, in which they remained for 2 hours.
• Subjects waited for 20 minutes in acclimatization of 21 °C ⁇ 1 °C and 50% ⁇ 5 RH in order to prevent the analysis from being biased by the sweat. After this period (THammam), new images of the subject’s face were obtained with the device Visia® CR and photos with the LightCam® device were performed on both hemifaces.
• Example 9 The results indicated that a statistically significant higher film surface was observed in the composition of the present invention (Example 9) compared to the composition of the state of the art (Example 8).
• the Figure 1 1 demonstrates the mean ⁇ standard error of the difference between time-points of Example 8 and Example 9 in relation to TO.
• Figure 12 demonstrates the mean ⁇ standard error for difference between time-points of Examples 8 and 9 in relation to TO.

Landscapes

• Health & Medical Sciences (AREA)
• Life Sciences & Earth Sciences (AREA)
• Veterinary Medicine (AREA)
• Public Health (AREA)
• General Health & Medical Sciences (AREA)
• Animal Behavior & Ethology (AREA)
• Epidemiology (AREA)
• Birds (AREA)
• Natural Medicines & Medicinal Plants (AREA)
• Chemical & Material Sciences (AREA)
• Microbiology (AREA)
• Mycology (AREA)
• Botany (AREA)
• Biotechnology (AREA)
• Engineering & Computer Science (AREA)
• Inorganic Chemistry (AREA)
• Dermatology (AREA)
• Pharmacology & Pharmacy (AREA)
• Medicinal Chemistry (AREA)
• Medical Informatics (AREA)
• Alternative & Traditional Medicine (AREA)
• Emergency Medicine (AREA)
• Cosmetics (AREA)

Applications Claiming Priority (1)

Publications (1)

Family

ID=80735508

Family Applications (1)

Country Status (5)

Families Citing this family (1)

Family Cites Families (23)

• 2022
  • 2022-02-25 EP EP22709552.8A patent/EP4482506A1/de active Pending
  • 2022-02-25 KR KR1020247016301A patent/KR20240093708A/ko active Pending
  • 2022-02-25 CN CN202280074208.0A patent/CN118302179A/zh active Pending
  • 2022-02-25 WO PCT/BR2022/050063 patent/WO2023159282A1/en not_active Ceased
  • 2022-04-14 FR FR2203437A patent/FR3133013A1/fr active Pending

Also Published As

Similar Documents

Legal Events